MorphoSys to Receive Milestone Payment for CNTO 1959 Phase 2 Program
MorphoSys AG has announced that Janssen Biotech, Inc. (formerly Centocor Ortho Biotech, Inc.) has initiated a phase 2 clinical trial in psoriasis patients with the HuCAL-derived antibody CNTO 1959.
The event triggered a clinical milestone payment to MorphoSys. Further financial details were not disclosed.
"With every clinical milestone and every new phase 2 start the time where the first HuCAL-based antibody drug could enter the market gets closer. MorphoSys's antibody pipeline has substantially matured over the last 18 months," commented Dr. Marlies Sproll, Chief Scientific Officer of MorphoSys AG.
In total, MorphoSys's clinical pipeline now comprises nine partnered programs in phase 1 and seven in phase 2 development as well as the Company's proprietary programs MOR103, which is in a phase 1b/2a trial for rheumatoid arthritis, MOR208, which is in a phase 1 trial for chronic lymphocytic leukemia and MOR202, which is in a phase 1/2a trial for multiple myeloma.